Latent tuberculosis needs attention

Archives of Pediatrics and Adolescent Medicine

Volumn 162, Issue 5, 2008, Pages 489-490

  Powell, Dwight A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

EDITORIAL; HUMAN; IMMIGRATION; IMMUNE RESPONSE; LUNG; LYMPHATIC SYSTEM; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REFUGEE; SOMALIA; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES; CASE MANAGEMENT; ECONOMICS; LUNG TUBERCULOSIS; MIGRATION; NOTE; PRESCHOOL CHILD; PUBLIC HEALTH SERVICE;

ANTITUBERCULAR AGENTS; CASE MANAGEMENT; CHILD, PRESCHOOL; EMIGRATION AND IMMIGRATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PUBLIC HEALTH PRACTICE; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; UNITED STATES;

EID: 43049149468     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpedi.162.5.489     Document Type: Editorial

References (13)

1. Dye C, Scheele S, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282(7):677-686.
2. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350(20):2060-2067.
3. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4, pt 2):S221-S247.
4. Lobato MN, Sun SJ, Moonan PK, et al. Underuse of effective measures to prevent and manage pediatric tuberculosis in the United States. Arch Pediatr Adolesc Med. 2008;162(5):426-431.
5. CDC immigration requirements: technical instructions for tuberculosis screening and treatment, 2007. http://www.cdc.gov/ncidod/dq/panel_2007.htm. Accessed February 18, 2008.
6. Centers for Disease Control. Trends in tuberculosis incidence - United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56(11):245-250.
7. Brassard P, Steensma C, Cadieux L, Lands LC. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country. Pediatrics. 2006;117(2):e148-e156.
8. Powell DA, Perkins L, Wang S-H, Hunt G, Ryan-Wenger N. Completion of therapy for latent tuberculosis in children of different nationalities. Pediatr Infect Dis J. In press.
9. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006;173(8):927-931.
10. Carter ER, Lee CM. Interpretation of the tuberculin skin test reaction by pediatric providers. Pediatr Infect Dis J. 2002;21(3):200-203.
11. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45(6):715-722.
12. Comprehensive Tuberculosis Elimination Act of 2007, HR 1532, 110th Cong (2007).
13. Comprehensive Tuberculosis Elimination Act of 2007, S 1551, 110th Cong (2007).